Roche (RHHBY) and Chiasma Inc. to Ally on Drug Development for Up to $600 Million
2/19/2013 6:58:50 AM
More...
|
Chiasma Inc. Closes $38.5 Million Equity Financing
7/23/2012 10:20:16 AM
More...
|
Chiasma Inc. Release: Data on Investigational Oral Octreolin™ for Acromegaly Demonstrate Growth Hormone Suppression
6/27/2012 9:31:44 AM
More...
|
Chiasma Inc. to Present at the UBS Global Life Sciences Conference
9/14/2011 10:54:14 AM
More...
|
Chiasma Inc.'s Octreolin(TM) (Oral Octreotide) Shown to Inhibit Growth Hormone in Healthy Subjects
6/6/2011 11:41:29 AM
More...
|
Chiasma Inc. to Present at the UBS Global Life Sciences Conference
9/21/2010 8:31:44 AM
More...
|
Chiasma (Israel) Ltd. Receives Orphan Drug Designation From the FDA for Octreolin(TM) for the Oral Treatment of Acromegaly
6/28/2010 9:01:15 AM
More...
|
Chiasma Secures $11 Million
1/12/2009 8:54:46 AM
More...
|
Chiasma Raises $44 Million Series C To Fund Clinical Testing, Advance Technology
11/15/2006 9:42:22 AM
More...
|
Chiasma Inc. Completes $6.2M Series B Round; New US Operations In Boston
10/19/2005 5:09:16 PM
More...
|